LinTT1-Functionalized Hybrid Lipid-Polymer Nanoparticles for Glioblastoma Targeting

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis and limited treatment options.
• Effective drug delivery to GBM remains a significant challenge due to the blood-brain barrier and tumor heterogeneity.

Purpose of the Study:

• To develop and evaluate hybrid lipid-polymer nanoparticles (HLPNs) functionalized with the C-end Rule peptide LinTT1 for targeted delivery to GBM.
• To assess the in vitro and in vivo efficacy of LinTT1-functionalized HLPNs loaded with temozolomide (TMZ) for GBM treatment.

Main Methods:

• Development of hybrid lipid-polymer nanoparticles (HLPNs) and functionalization with LinTT1 peptide (LinTT1-HLPNs).
• In vitro assessment of LinTT1-HLPNs binding selectivity to GBM cells and cytotoxicity of loaded temozolomide (LinTT1-HLPNs@TMZ).
• In vivo evaluation of LinTT1-HLPNs' tumor accumulation and tissue penetration in murine GBM models after intravenous injection.

Main Results:

• LinTT1-HLPNs exhibited selective binding to GBM cells in vitro.
• LinTT1-HLPNs@TMZ demonstrated significantly enhanced cytotoxicity compared to free temozolomide.
• In vivo studies showed enhanced accumulation of temozolomide in GBM tumor areas, confirming selective targeting and tissue penetration.

Conclusions:

• The LinTT1-HLPNs nanoplatform effectively targets GBM, improving drug delivery and therapeutic outcomes.
• This hybrid nanoparticle system, combined with a GBM-specific targeting peptide, offers a promising multistep approach to address key challenges in GBM therapy.